Overview
Molecular Testing for Thyroid Nodules
Mir-THYpe full can help prevent diagnostic surgeries by reclassifying an indeterminate thyroid nodule as negative (benign) or positive (malignant). It does this using molecular prognostic markers, which may also predict a more or less aggressive behavior of the nodule.
Nodules with negative prognostic markers may be eligible for more limited surgery, which can preserve part of the thyroid function.
Mir-THYpe Target
The mir-THYpe target test looks for the molecular changes that targeted therapies are designed to act on. Targeted therapies are drugs specifically designed for signaling pathways altered by mutations (DNA) or somatic fusions (RNA) directly in the tumor.
- Analyzes mutations (DNA) and fusions (RNA) in 52 “druggable” genes
- Includes all molecular alterations used for target-drug selection in advanced thyroid cancer (BRAF, NTRK, ALK and RET genes)
Why Choose Mir-THYpe?
- Reclassifies indeterminate nodules as benign or malignant
- Can help prevent diagnostic surgery
- Prognostic markers indicate how aggressive a nodule may be
- Can allow partial surgery that preserves thyroid function